On 15 May 2024, Formycon announced its partnership with MS Pharma in MENA for the commercialisation of its aflibercept biosimilar FYB203. Klinge Pharma GmbH, which holds the global commercialisation rights for Formycon’s FYB203, granted MS Pharma exclusive rights to license, commercialise, and produce FYB203 in Saudi Arabia for the Middle East and North Africa (MENA).
MS Pharma markets Formycon’s Ravegza® (FYB201, ranibizumab) in the MENA region.
In June 2023, the FDA accepted Formycon’s BLA for FYB203 and its MAA application was accepted by EMA in December 2023.